NUVB · Insider Trading
Nuvation Bio Inc.
Every open-market purchase and sale reported by NUVB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-21 | Gary Hattersley | CHIEF SCIENTIFIC OFFICER | MIXED | — | −$522.24K |
| 2026-07-17 | Philippe Sauvage | Chief Financial Officer | M | +40,000 | +$86.80K |
| 2026-06-24 | Philippe Sauvage | Chief Financial Officer | MIXED | — | −$182.93K |
| 2026-06-24 | Stacy Markel | CHIEF PEOPLE OFFICER | MIXED | — | −$523.94K |
| 2026-06-24 | Kerry Wentworth | CHIEF REGULATORY OFFICER | MIXED | — | −$194.60K |
| 2026-06-11 | Robert Mashal | Director | Buy | +25,000 | +$118.25K |
| 2026-05-26 | Robert B Bazemore | Director | A | +123,397 deriv. | — |
| 2026-05-26 | Xiangmin Cui | Director | A | +76,923 deriv. | — |
| 2026-05-26 | Kathryn E Falberg | Director | A | +123,397 deriv. | — |
| 2026-05-26 | Xiangmin Cui | Director | A | +123,397 deriv. | — |
| 2026-05-26 | W Anthony Vernon | Director | A | +123,397 deriv. | — |
| 2026-05-26 | Robert Mashal | Director | A | +123,397 deriv. | — |
| 2026-05-26 | Kim D Blickenstaff | Director | A | +123,397 deriv. | — |
| 2026-04-21 | Kerry Wentworth | CHIEF REGULATORY OFFICER | MIXED | — | −$76.60K |
| 2026-04-21 | Dongfang Liu | CHIEF MEDICAL OFFICER | MIXED | — | −$154.00K |
| 2026-04-08 | Kerry Wentworth | CHIEF REGULATORY OFFICER | MIXED | — | −$522.56K |
| 2026-03-03 | David Hung | PRESIDENT AND CEO | A | +1,995,012 deriv. | — |
| 2026-03-03 | Stacy Markel | CHIEF PEOPLE OFFICER | A | — | — |
| 2026-03-03 | Dongfang Liu | CHIEF MEDICAL OFFICER | A | +748,130 deriv. | — |
| 2026-03-03 | Colleen Sjogren | Chief Commercial Officer | A | — | — |
| 2026-03-03 | Moses Makunje | SEE REMARKS | A | +50,761 | — |
| 2026-03-03 | Xiangmin Cui | Director | A | +74,813 deriv. | — |
| 2026-03-03 | Kerry Wentworth | CHIEF REGULATORY OFFICER | A | — | — |
| 2026-03-03 | Philippe Sauvage | Chief Financial Officer | A | — | — |
| 2026-03-03 | David C. Hanley | CHIEF TECHNICAL OPERATIONS | A | +748,130 deriv. | — |
| 2026-03-03 | Gary Hattersley | CHIEF SCIENTIFIC OFFICER | A | +748,130 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Robert Mashal | Director | 225,000 | $981.00K |
| Stacy Markel | CHIEF PEOPLE OFFICER | 122,971 | $536.15K |
| Gary Hattersley | CHIEF SCIENTIFIC OFFICER | 100,000 | $436.00K |
| Colleen Sjogren | Chief Commercial Officer | 84,000 | $366.24K |
| Moses Makunje | SEE REMARKS | 68,137 | $297.08K |
| Philippe Sauvage | Chief Financial Officer | 54,130 | $236.01K |
| Kerry Wentworth | CHIEF REGULATORY OFFICER | 53,000 | $231.08K |
| Dongfang Liu | CHIEF MEDICAL OFFICER | 18,000 | $78.48K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NUVB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.